Second, plasma HO-1 concentrations in patients with atypical Parkinsonism, such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), need to be measured in the future to determine the specificity of HO-1 as a marker of idiopathic PD. This evidence concerns the gene HMOX1 and Parkinson disease.